---
date created: 2024-11-16
dg-publish: true
tags:
  - meds
---
**Class:**
- Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

**Mechanism of Action (MOA):**
- Inhibits VMAT2, decreasing the release of monoamines such as dopamine, which helps manage tardive dyskinesia symptoms.

**Indications/Uses:**
- Tardive dyskinesia

**Side Effects:**
- Somnolence
- Fatigue
- Dry mouth
- Constipation
- Balance disorders

**Adverse Effects:**
- QT prolongation
- Neuroleptic malignant syndrome (rare)
- Depression or suicidal thoughts

**Nursing Teaching and Implications:**
- Educate about the potential for drowsiness and advise caution when driving or operating machinery.
- Monitor ECG in patients with risk factors for QT prolongation.
- Assess for changes in mood or behavior.
- Advise taking the medication consistently at the same time each day.

**Contraindications:**
- Known hypersensitivity to valbenazine